{"transactions":[{"id":4615061,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":183131,"kind":"person","name":"Fairmount Healthcare Co-Invest VI L.P.","position":3,"cik":"0002124208","reported_name":"Fairmount Healthcare Co-Invest VI L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-10T21:44:57.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":48445,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 48,445 shares of the Issuer's common stock. This option will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\") and Fairmount Healthcare Co-Invest VI L.P. (\"Co-Invest\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":48445,"derivative":{"exercise_price":26.2,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":48445},"source":{"system":"sec-edgar","filing":"0001193125-26-388142","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2124208/000119312526388142/ownership.xml","form_type":"4"}},{"id":3180,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3179,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3178,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3177,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47758,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":47758},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3176,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6743321,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6743321},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3175,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51166,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3174,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51166,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3173,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":340855,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":690295,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represented the right to purchase 10,370 shares of the Issuer's common stock, which vested on the one-year anniversary of the 6/5/2024 grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":690294,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":31838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represented the vested portion of the total right to purchase 47,758 shares of the Issuer's common stock, which vested in three approximately equal annual installments beginning on the first anniversary of the 7/13/2023 grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":31838},"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":690293,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":10370,"price":43.85,"value":454724.5,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":340855,"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":690292,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":31838,"price":17,"value":541246.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":330485,"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":705651,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-07-20T21:30:09.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":525897,"price":14.499,"value":7624980.603,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2294037,"derivative":{"exercise_price":0.001,"underlying":"Ordinary Shares","underlying_shares":525897},"source":{"system":"sec-edgar","filing":"0001104659-26-085113","document":"tm2620801-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/tm2620801-1_4seq1.xml","form_type":"4"}},{"id":705650,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-07-20T21:30:09.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":853450,"price":14.5,"value":12375025.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3601316,"source":{"system":"sec-edgar","filing":"0001104659-26-085113","document":"tm2620801-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/tm2620801-1_4seq1.xml","form_type":"4"}},{"id":722024,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":34247,"kind":"person","name":"Fairmount Healthcare Co-Invest III L.P.","position":3,"cik":"0002009690","reported_name":"Fairmount Healthcare Co-Invest III L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-07-02T01:30:15.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":42641,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":94497,"derivative":{"underlying":"Common Stock","underlying_shares":3553410},"source":{"system":"sec-edgar","filing":"0001104659-26-080009","document":"tm2619616-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000110465926080009/tm2619616-1_4seq1.xml","form_type":"4"}},{"id":722023,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":34247,"kind":"person","name":"Fairmount Healthcare Co-Invest III L.P.","position":3,"cik":"0002009690","reported_name":"Fairmount Healthcare Co-Invest III L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T01:30:15.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":3553410,"price":84.43,"value":300014406.3,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1131954,"source":{"system":"sec-edgar","filing":"0001104659-26-080009","document":"tm2619616-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000110465926080009/tm2619616-1_4seq1.xml","form_type":"4"}},{"id":722022,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":34247,"kind":"person","name":"Fairmount Healthcare Co-Invest III L.P.","position":3,"cik":"0002009690","reported_name":"Fairmount Healthcare Co-Invest III L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T01:30:15.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":3553410,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":4685364,"source":{"system":"sec-edgar","filing":"0001104659-26-080009","document":"tm2619616-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000110465926080009/tm2619616-1_4seq1.xml","form_type":"4"}},{"id":728581,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-24T01:56:26.000Z","date":"2026-06-23","kind":"exercise","planned":false,"acquired":false,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":666680},"source":{"system":"sec-edgar","filing":"0001104659-26-076967","document":"tm2618664-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000110465926076967/tm2618664-2_4seq1.xml","form_type":"4"}},{"id":728580,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T01:56:26.000Z","date":"2026-06-23","kind":"sale","planned":false,"acquired":false,"shares":4684781,"price":85.31,"value":399658667.11,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-076967","document":"tm2618664-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000110465926076967/tm2618664-2_4seq1.xml","form_type":"4"}},{"id":728579,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T01:56:26.000Z","date":"2026-06-23","kind":"exercise","planned":false,"acquired":true,"shares":666680,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":4684781,"source":{"system":"sec-edgar","filing":"0001104659-26-076967","document":"tm2618664-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000110465926076967/tm2618664-2_4seq1.xml","form_type":"4"}},{"id":742002,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39347,"kind":"person","name":"Fairmount Healthcare Co-Invest IV L.P.","position":3,"cik":"0002042283","reported_name":"Fairmount Healthcare Co-Invest IV L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:37:08.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":34843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Tomas Kiselak's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II LP (\"Fund II\") and Fairmount Healthcare Co-Invest IV L.P. (\"Co-Invest\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":34843,"derivative":{"exercise_price":15.22,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":34843},"source":{"system":"sec-edgar","filing":"0001193125-26-267706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042283/000119312526267706/ownership.xml","form_type":"4"}},{"id":741195,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":1,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:30:27.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":17901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":17901,"derivative":{"exercise_price":31.98,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":17901},"source":{"system":"sec-edgar","filing":"0001193125-26-267665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526267665/ownership.xml","form_type":"4"}},{"id":751228,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:46:38.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II LP (\"Fund II\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040575","document":"wk-form4_1780530395.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040575/wk-form4_1780530395.xml","form_type":"4"}},{"id":753109,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":34247,"kind":"person","name":"Fairmount Healthcare Co-Invest III L.P.","position":3,"cik":"0002009690","reported_name":"Fairmount Healthcare Co-Invest III L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T20:45:11.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":9136,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 9,136 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2026, subject to the recipient's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II LP (\"Fund II\") and Fairmount Healthcare Co-Invest III L.P. (\"Co-Invest\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":9136,"derivative":{"exercise_price":55.23,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":9136},"source":{"system":"sec-edgar","filing":"0001104659-26-070135","document":"tm2616798-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000110465926070135/tm2616798-1_4seq1.xml","form_type":"4"}},{"id":822489,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T20:30:31.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":20,"value":3000000.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2359025,"source":{"system":"sec-edgar","filing":"0001104659-26-038546","document":"tm2610877-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926038546/tm2610877-1_4seq1.xml","form_type":"4"}},{"id":828401,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T18:03:28.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":37313,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II LP (\"Fund II\") and Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":37313,"derivative":{"exercise_price":23.05,"expiration_date":"2036-03-23","underlying":"Common Stock","underlying_shares":37313},"source":{"system":"sec-edgar","filing":"0001193125-26-124471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526124471/ownership.xml","form_type":"4"}},{"id":907942,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":2904,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest V L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":574,"derivative":{"underlying":"Common Stock","underlying_shares":2904000},"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":907941,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":5809,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1148,"derivative":{"underlying":"Common Stock","underlying_shares":5809000},"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":907940,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":2904000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest V L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2904000,"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":907939,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":5809000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":5809000,"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":933154,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T01:07:15.000Z","date":"2026-01-22","kind":"sale","planned":false,"acquired":false,"shares":1750000,"price":76.3,"value":133525000.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":298647,"source":{"system":"sec-edgar","filing":"0001104659-26-005921","document":"tm263873-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926005921/tm263873-1_4seq1.xml","form_type":"4"}},{"id":977414,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2025-12-08T21:30:15.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":131434,"price":13.409,"value":1762398.506,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1768140,"derivative":{"exercise_price":0.001,"underlying":"Ordinary Shares","underlying_shares":131434},"source":{"system":"sec-edgar","filing":"0001104659-25-119320","document":"tm2532982-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925119320/tm2532982-1_4seq1.xml","form_type":"4"}},{"id":977413,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-08T21:30:15.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":1360000,"price":13.41,"value":18237600.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2747866,"source":{"system":"sec-edgar","filing":"0001104659-25-119320","document":"tm2532982-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925119320/tm2532982-1_4seq1.xml","form_type":"4"}},{"id":1020686,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-09T20:15:16.000Z","date":"2025-10-07","kind":"purchase","planned":false,"acquired":true,"shares":316219,"price":19,"value":6008161.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported\nsecurities, except to the extent of their pecuniary interest therein."}],"balance_after":2209025,"source":{"system":"sec-edgar","filing":"0001104659-25-098362","document":"tm2528449-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465925098362/tm2528449-1_4seq1.xml","form_type":"4"}},{"id":1021657,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39347,"kind":"person","name":"Fairmount Healthcare Co-Invest IV L.P.","position":3,"cik":"0002042283","reported_name":"Fairmount Healthcare Co-Invest IV L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2025-10-08T20:15:17.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":855047,"price":9.1399,"value":7815044.0753,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and Pre-Funded Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest IV L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":855047,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":855047},"source":{"system":"sec-edgar","filing":"0001104659-25-097921","document":"tm2528311-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042283/000110465925097921/tm2528311-1_4seq1.xml","form_type":"4"}},{"id":1021656,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39347,"kind":"person","name":"Fairmount Healthcare Co-Invest IV L.P.","position":3,"cik":"0002042283","reported_name":"Fairmount Healthcare Co-Invest IV L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-08T20:15:17.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":1333126,"price":9.14,"value":12184771.64,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and Pre-Funded Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest IV L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1897677,"source":{"system":"sec-edgar","filing":"0001104659-25-097921","document":"tm2528311-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042283/000110465925097921/tm2528311-1_4seq1.xml","form_type":"4"}},{"id":1035872,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":34247,"kind":"person","name":"Fairmount Healthcare Co-Invest III L.P.","position":3,"cik":"0002009690","reported_name":"Fairmount Healthcare Co-Invest III L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T21:33:05.000Z","date":"2025-09-17","kind":"grant","planned":false,"acquired":true,"shares":333340,"price":15,"value":5000100.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1131954,"source":{"system":"sec-edgar","filing":"0001104659-25-091747","document":"tm2526585-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000110465925091747/tm2526585-1_4seq1.xml","form_type":"4"}},{"id":1103559,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:48:57.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 9,023 of the Issuer's ordinary shares, which vest in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (\"Fairmount\"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or shares received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying ordinary shares. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061819","document":"tm2518376-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061819/tm2518376-17_4seq1.xml","form_type":"4"}},{"id":1104570,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-21T00:06:44.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14461,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":14461,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-25-061278","document":"tm2518364-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465925061278/tm2518364-2_4seq1.xml","form_type":"4"}},{"id":1104569,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-21T00:06:44.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14461,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":14461,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-25-061278","document":"tm2518364-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465925061278/tm2518364-2_4seq1.xml","form_type":"4"}},{"id":1112844,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:34:14.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC (\"Fairmount\" and each such investment vehicle, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":18500,"derivative":{"exercise_price":11.94,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-25-058927","document":"tm2517684-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465925058927/tm2517684-5_4seq1.xml","form_type":"4"}},{"id":1120884,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":1,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:19:21.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":44700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC  (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":44700,"derivative":{"exercise_price":5.64,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":44700},"source":{"system":"sec-edgar","filing":"0000950170-25-082349","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017025082349/ownership.xml","form_type":"4"}},{"id":1126287,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":34247,"kind":"person","name":"Fairmount Healthcare Co-Invest III L.P.","position":3,"cik":"0002009690","reported_name":"Fairmount Healthcare Co-Invest III L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-03T20:30:57.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 17,500 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2025, subject to the recipient's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (\"Fairmount\"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":17500,"derivative":{"exercise_price":11.77,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-25-055989","document":"tm2517029-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000110465925055989/tm2517029-1_4seq1.xml","form_type":"4"}},{"id":1127187,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":2,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":4,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:39:53.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein."}],"balance_after":25000,"derivative":{"exercise_price":15.55,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001636282-25-000069","document":"wk-form4_1748896783.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000069/wk-form4_1748896783.xml","form_type":"4"}},{"id":1127186,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":2,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":4,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:39:53.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein."}],"balance_after":25000,"derivative":{"exercise_price":15.55,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001636282-25-000069","document":"wk-form4_1748896783.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000069/wk-form4_1748896783.xml","form_type":"4"}},{"id":1162511,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-01T22:16:57.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":23017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (\"Fairmount\"), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":23017,"derivative":{"exercise_price":10.14,"expiration_date":"2035-04-29","underlying":"Common Stock","underlying_shares":23017},"source":{"system":"sec-edgar","filing":"0000950170-25-062123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000095017025062123/ownership.xml","form_type":"4"}},{"id":1356243,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-11-21T23:30:05.000Z","date":"2024-11-19","kind":"exercise","planned":false,"acquired":false,"shares":160,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Following receipt of the Requisite Stockholder Approval, each share of Series A Convertible Preferred Stock automatically converted into 1,000 shares of Common Stock. The Series A Convertible Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 14, 2024, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (\"Series A Convertible Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock, 160 shares of Series A Convertible Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") were converted into 160,000 shares of Common Stock, effective at 5:00 pm, Eastern Time on November 19, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Following receipt of the Requisite Stockholder Approval, each share of Series A Convertible Preferred Stock automatically converted into 1,000 shares of Common Stock. The Series A Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Following receipt of the Requisite Stockholder Approval, each share of Series A Convertible Preferred Stock automatically converted into 1,000 shares of Common Stock. The Series A Convertible Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Fairmount Healthcare Co-Invest III L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001213900-24-101116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/907654/000121390024101116/ownership.xml","form_type":"4"}},{"id":1356242,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-21T23:30:05.000Z","date":"2024-11-19","kind":"exercise","planned":false,"acquired":true,"shares":160000,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 14, 2024, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (\"Series A Convertible Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock, 160 shares of Series A Convertible Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") were converted into 160,000 shares of Common Stock, effective at 5:00 pm, Eastern Time on November 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 14, 2024, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (\"Series A Convertible Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock, 160 shares of Series A Convertible Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") were converted into 160,000 shares of Common Stock, effective at 5:00 pm, Eastern Time on November 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Fairmount Healthcare Co-Invest III L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":798614,"source":{"system":"sec-edgar","filing":"0001213900-24-101116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000121390024101116/ownership.xml","form_type":"4"}},{"id":1404563,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":37000,"derivative":{"exercise_price":17,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404562,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2614287,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":301077},"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404561,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":6163236,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":709794},"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404560,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2195871,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":252890},"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404559,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Convertible Preferred Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":357143,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41130},"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404558,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":17,"value":5100000.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported \"Amount of Securities Beneficially Owned Following Reported Transactions.\" This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1892806,"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404557,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":301077,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported \"Amount of Securities Beneficially Owned Following Reported Transactions.\" This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1592806,"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404556,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":709794,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported \"Amount of Securities Beneficially Owned Following Reported Transactions.\" This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1291729,"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404555,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":252890,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported \"Amount of Securities Beneficially Owned Following Reported Transactions.\" This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":581935,"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1404554,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:56:05.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":41130,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported \"Amount of Securities Beneficially Owned Following Reported Transactions.\" This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":329045,"source":{"system":"sec-edgar","filing":"0001104659-24-100766","document":"tm2424157-13_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100766/tm2424157-13_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-16"}},{"id":1406332,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":37000,"derivative":{"exercise_price":17,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406331,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2614287,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":301077},"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406330,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":6163236,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":709794},"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406329,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2195871,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":252890},"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406328,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Convertible Preferred Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":357143,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41130},"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406327,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":17,"value":5100000.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1604891,"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406326,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":301077,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1304891,"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406325,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":709794,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1003814,"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406324,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":252890,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":294020,"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1406323,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":41130,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. (\"Fund II\"). The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":41140,"source":{"system":"sec-edgar","filing":"0001104659-24-100330","document":"tm2424157-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924100330/tm2424157-1_4seq1.xml","form_type":"4"}},{"id":1408070,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-09-13T20:55:08.000Z","date":"2024-09-11","kind":"grant","planned":false,"acquired":true,"shares":160,"price":23000,"value":3680000.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Following stockholder approval of the conversion of the Series A non-voting convertible preferred stock (the \"Series A Preferred Stock\") into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"The shares of Series A Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Following stockholder approval of the conversion of the Series A non-voting convertible preferred stock (the \"Series A Preferred Stock\") into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Following stockholder approval of the conversion of the Series A non-voting convertible preferred stock (the \"Series A Preferred Stock\") into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":160,"derivative":{"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001213900-24-078633","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/907654/000121390024078633/ownership.xml","form_type":"4"}},{"id":1408069,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T20:55:08.000Z","date":"2024-09-11","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":23,"value":6325000.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":638614,"source":{"system":"sec-edgar","filing":"0001213900-24-078633","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000121390024078633/ownership.xml","form_type":"4"}},{"id":1466997,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":1,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:05:06.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079044","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024079044/ownership.xml","form_type":"4"}},{"id":1480186,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":1,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T23:11:20.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":44700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC  (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":44700,"derivative":{"exercise_price":8.92,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":44700},"source":{"system":"sec-edgar","filing":"0000950170-24-073231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024073231/ownership.xml","form_type":"4"}},{"id":1486072,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T00:00:12.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":10370,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-24-069790","document":"tm2416491-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924069790/tm2416491-7_4seq1.xml","form_type":"4"}},{"id":1486071,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T00:00:12.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":10370,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-24-069790","document":"tm2416491-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465924069790/tm2416491-7_4seq1.xml","form_type":"4"}},{"id":1513790,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-16T20:10:28.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":11323,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":11323,"derivative":{"exercise_price":39.29,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":11323},"source":{"system":"sec-edgar","filing":"0000950170-24-061084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024061084/ownership.xml","form_type":"4"}},{"id":1513789,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-16T20:10:28.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":11323,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":11323,"derivative":{"exercise_price":39.29,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":11323},"source":{"system":"sec-edgar","filing":"0000950170-24-061084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024061084/ownership.xml","form_type":"4"}},{"id":1535272,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-04-25T20:55:38.000Z","date":"2024-04-25","kind":"exercise","planned":false,"acquired":false,"shares":90992,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. (\"Fund II\") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") for 3,639,680 shares of Common Stock, effective on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":346045,"derivative":{"underlying":"Common Stock","underlying_shares":3639680},"source":{"system":"sec-edgar","filing":"0000950170-24-048457","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024048457/ownership.xml","form_type":"4"}},{"id":1535271,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-25T20:55:38.000Z","date":"2024-04-25","kind":"exercise","planned":false,"acquired":true,"shares":3639680,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. (\"Fund II\") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") for 3,639,680 shares of Common Stock, effective on April 25, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":4018101,"source":{"system":"sec-edgar","filing":"0000950170-24-048457","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024048457/ownership.xml","form_type":"4"}},{"id":1556374,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":221426,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":6743321,"derivative":{"underlying":"Common Stock","underlying_shares":6521895},"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1556373,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":221426,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":221426},"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1556372,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":55913,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":2048647,"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1556371,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":55913,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1665211,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:31:31.000Z","date":"2024-01-29","kind":"other","planned":true,"acquired":true,"shares":51166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":51166,"source":{"system":"sec-edgar","filing":"0001104659-24-008835","document":"tm244753-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924008835/tm244753-2_4seq1.xml","form_type":"4"}},{"id":1665210,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:31:31.000Z","date":"2024-01-29","kind":"other","planned":true,"acquired":true,"shares":51166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":51166,"source":{"system":"sec-edgar","filing":"0001104659-24-008835","document":"tm244753-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924008835/tm244753-2_4seq1.xml","form_type":"4"}},{"id":1665209,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:31:31.000Z","date":"2024-01-29","kind":"other","planned":true,"acquired":false,"shares":892529,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P. (\"Fund I\"), Fairmount Healthcare Fund II L.P. (\"Fund II\") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-008835","document":"tm244753-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924008835/tm244753-2_4seq1.xml","form_type":"4"}},{"id":1672041,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2024-01-25T00:02:49.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":832333,"price":11.999,"value":9987163.667,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Consists of Pre-Funded Warrants to purchase up to 832,333 shares of common stock purchased by Fund II from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of Pre-Funded Warrants to purchase up to 832,333 shares of common stock held of record by Fund II. Fairmount is the investment manager for Fund II. The general partner of Fairmount is Fairmount GP, of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":832333,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":832333},"source":{"system":"sec-edgar","filing":"0000950170-24-007136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024007136/ownership.xml","form_type":"4"}},{"id":1672040,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-25T00:02:49.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":834334,"price":12,"value":10012008.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 834,334 shares of common stock purchased by Fairmount Healthcare Fund II LP (\"Fund II\") from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP (\"Fund I\"), (ii) 2,641,834 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2762837,"source":{"system":"sec-edgar","filing":"0000950170-24-007136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024007136/ownership.xml","form_type":"4"}},{"id":1697956,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":true,"shares":406038,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":406038,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1697955,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":true,"shares":406038,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":406038,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1697954,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":false,"shares":3435480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P. (\"Fund I\"), Fairmount Healthcare Fund II L.P. (\"Fund II\") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1716308,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-12-11T17:41:01.000Z","date":"2023-12-07","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":600,"value":10000200.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":666680},"source":{"system":"sec-edgar","filing":"0000950170-23-069455","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023069455/ownership.xml","form_type":"4"}},{"id":1728666,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-11-28T16:05:26.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":85887,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3435480},"source":{"system":"sec-edgar","filing":"0000950170-23-066399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023066399/ownership.xml","form_type":"4"}},{"id":1728665,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T16:05:26.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":3435480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3435480,"source":{"system":"sec-edgar","filing":"0000950170-23-066399","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023066399/ownership.xml","form_type":"4"}},{"id":1767560,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T20:00:40.000Z","date":"2023-09-29","kind":"purchase","planned":false,"acquired":true,"shares":24670,"price":13.63,"value":336252.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 24,670 shares of common stock purchased by Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.45 to $13.645. The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP (\"Fund I\"), (ii) 1,807,500 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1928503,"source":{"system":"sec-edgar","filing":"0001104659-23-106378","document":"tm2327394-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000110465923106378/tm2327394-1_4seq1.xml","form_type":"4"}},{"id":1772144,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T21:09:20.000Z","date":"2023-09-26","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":13.15,"value":394500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 30,000 shares of common stock purchased by Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP (\"Fund I\"), (ii) 1,782,830 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1903833,"source":{"system":"sec-edgar","filing":"0001104659-23-104808","document":"tm2327182-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000110465923104808/tm2327182-1_4seq1.xml","form_type":"4"}},{"id":1775432,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T20:23:57.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":13.2,"value":396000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 30,000 shares of common stock purchased by Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP (\"Fund I\"), (ii) 1,752,830 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1873833,"source":{"system":"sec-edgar","filing":"0000899243-23-019370","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924323019370/doc4.xml","form_type":"4"}},{"id":1782082,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-14T01:17:54.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":6500,"derivative":{"exercise_price":11.2,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0000950170-23-048022","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017023048022/ownership.xml","form_type":"4"}},{"id":1782081,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T01:17:54.000Z","date":"2023-09-13","kind":"purchase","planned":false,"acquired":true,"shares":9367,"price":11.76,"value":110155.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Consists of (i) 281 shares of common stock purchased by Fund I and (ii) 9,086 shares of common stock purchased by Fund II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $10.90 to $12.50 The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of (i) 58,857 shares of common stock held of record by Fund I, (ii) 1,722,830 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC."}],"balance_after":1843833,"source":{"system":"sec-edgar","filing":"0000950170-23-048022","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017023048022/ownership.xml","form_type":"4"}},{"id":1782080,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":3,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T01:17:54.000Z","date":"2023-09-12","kind":"purchase","planned":false,"acquired":true,"shares":14887,"price":10.85,"value":161523.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of (i) 447 shares of common stock purchased by Fairmount Healthcare Fund LP (\"Fund I\") and (ii) 14,440 shares of common stock purchased by Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.415 to $11.00. The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (i) 58,576 shares of common stock held of record by Fund I, (ii) 1,713,744 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1834466,"source":{"system":"sec-edgar","filing":"0000950170-23-048022","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017023048022/ownership.xml","form_type":"4"}}],"next_cursor":"2023-09-14T01:17:54.000000Z,1782080"}